{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T02:13:40Z","timestamp":1794363220602,"version":"4.9.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,26]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Axicabtagene ciloleucel (axi-cel) is an effective chimeric antigen receptor T-cell (CAR-T) therapy for relapsed or refractory (R\/R) large B-cell lymphoma (LBCL). However, controlling cytokine release syndrome (CRS) and immune effector cell\u2013associated neurotoxicity syndrome (ICANS) without compromising therapeutic efficacy remains a difficult challenge. In July 2020, our center adopted a toxicity management protocol modified from cohort 4 of the registrational ZUMA-1 trial, with earlier steroid use and incorporation of anakinra. To evaluate this change, we conducted a retrospective analysis of patients receiving axi-cel for R\/R LBCL in the third-line setting from January 2018 through April 2023. The outcomes of interest were toxicity incidence\/duration, treatment response, CAR-T expansion, and drug\/health care utilization. Of the 195 identified patients, the postchange cohort (n = 103) had higher rates of anakinra (22% vs 5%) and steroid use (88% vs 71%) use than the comparator cohort (n = 92), without increases in cumulative steroid dose. Overall CRS and ICANS rates were similar, with directionally lower severe (grade 3+) ICANS rates in the postchange cohort. A significant reduction in CRS and ICANS duration was observed with the new protocol (adjusted estimate, \u02d70.93 days [95% confidence interval (CI), \u02d71.67 to \u02d70.19] and \u02d72.49 days [95% CI, \u02d74.96 to \u02d70.03], respectively). Day 7 CAR-T expansion was lower in the postchange cohort, possibly due to earlier steroid use. However, efficacy outcomes, intensive care unit admission rates, and hospitalization length were similar between the cohorts. This study supports earlier intervention for CAR-T toxicities and establishes anakinra as a safe and effective alternative toxicity management drug to tocilizumab.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025019031","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T20:40:09Z","timestamp":1773952809000},"page":"3313-3323","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Early steroid and anakinra use to manage axicabtagene ciloleucel toxicity reduces the total duration of CRS and ICANS"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3121-2415","authenticated-orcid":false,"given":"William L.","family":"Wang","sequence":"first","affiliation":[{"name":"1Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dasom","family":"Lee","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edna","family":"Cheung","sequence":"additional","affiliation":[{"name":"3Department of Pharmacy, Stanford Health Care, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6337-9079","authenticated-orcid":false,"given":"Alexandria","family":"Jensen","sequence":"additional","affiliation":[{"name":"4Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1731-085X","authenticated-orcid":false,"given":"Masooma Shifa","family":"Rana","sequence":"additional","affiliation":[{"name":"1Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anmol","family":"Goyal","sequence":"additional","affiliation":[{"name":"1Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hamilton","sequence":"additional","affiliation":[{"name":"1Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1033-1498","authenticated-orcid":false,"given":"Nima","family":"Ghalehsari","sequence":"additional","affiliation":[{"name":"1Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Latchford","sequence":"additional","affiliation":[{"name":"1Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5865-0327","authenticated-orcid":false,"given":"Brian","family":"Scott","sequence":"additional","affiliation":[{"name":"5Division of Neurology & Neurological Sciences, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayasindhu","family":"Mallampet","sequence":"additional","affiliation":[{"name":"6Cancer Correlative Science Unit, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Heng","sequence":"additional","affiliation":[{"name":"1Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0553-617X","authenticated-orcid":false,"given":"Humza","family":"Khan","sequence":"additional","affiliation":[{"name":"1Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3874-5847","authenticated-orcid":false,"given":"Muhammad Samsoor","family":"Zarak","sequence":"additional","affiliation":[{"name":"1Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2477-7888","authenticated-orcid":false,"given":"Claire","family":"Lohman","sequence":"additional","affiliation":[{"name":"6Cancer Correlative Science Unit, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bita","family":"Sahaf","sequence":"additional","affiliation":[{"name":"6Cancer Correlative Science Unit, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3288-7614","authenticated-orcid":false,"given":"Surbhi","family":"Sidana","sequence":"additional","affiliation":[{"name":"1Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Kai","family":"Weng","sequence":"additional","affiliation":[{"name":"1Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2702-0381","authenticated-orcid":false,"given":"Melody","family":"Smith","sequence":"additional","affiliation":[{"name":"1Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushma","family":"Bharadwaj","sequence":"additional","affiliation":[{"name":"1Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2356-3354","authenticated-orcid":false,"given":"Matthew J.","family":"Frank","sequence":"additional","affiliation":[{"name":"1Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0717-4305","authenticated-orcid":false,"given":"David B.","family":"Miklos","sequence":"additional","affiliation":[{"name":"1Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8291-1796","authenticated-orcid":false,"given":"Saurabh","family":"Dahiya","sequence":"additional","affiliation":[{"name":"1Division of Blood and Marrow Transplantation & Cellular Therapy, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"issue":"26","key":"2026052610380263500_bib1","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"2026052610380263500_bib2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"10343","key":"2026052610380263500_bib3","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar","year":"2022","journal-title":"The Lancet"},{"issue":"2","key":"2026052610380263500_bib4","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"35","key":"2026052610380263500_bib5","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026052610380263500_bib6","first-page":"705","article-title":"Spotlight on tocilizumab in the treatment of CAR-T-cell-induced cytokine release syndrome: clinical evidence to date","volume":"16","author":"Si","year":"2020","journal-title":"Ther Clin Risk Manag"},{"issue":"11","key":"2026052610380263500_bib7","first-page":"1065","article-title":"Tocilizumab prophylaxis following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"30","author":"Locke","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"3","key":"2026052610380263500_bib8","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/bjh.17673","article-title":"Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"195","author":"Topp","year":"2021","journal-title":"Br J Haematol"},{"key":"2026052610380263500_bib9","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jcrc.2020.04.012","article-title":"Critical care capacity during the COVID-19 pandemic: global availability of intensive care beds","volume":"58","author":"Ma","year":"2020","journal-title":"J Crit Care"},{"issue":"21","key":"2026052610380263500_bib10","doi-asserted-by":"crossref","first-page":"E771","DOI":"10.1503\/cmaj.210531","article-title":"Managing drug shortages during a pandemic: tocilizumab and COVID-19","volume":"193","author":"Verma","year":"2021","journal-title":"CMAJ Can Med Assoc J"},{"issue":"2","key":"2026052610380263500_bib11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0165-5728(94)90005-1","article-title":"Blood-borne interleukin-1 receptor antagonist crosses the blood-brain barrier","volume":"55","author":"Gutierrez","year":"1994","journal-title":"J Neuroimmunol"},{"issue":"6","key":"2026052610380263500_bib12","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"issue":"6","key":"2026052610380263500_bib13","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"issue":"9","key":"2026052610380263500_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2020.04.020","article-title":"Myeloma CAR-T CRS management with IL-1R antagonist anakinra","volume":"20","author":"Jatiani","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"21","key":"2026052610380263500_bib15","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1158\/1078-0432.CCR-23-0568","article-title":"FDA approval summary: axicabtagene ciloleucel for second-line treatment of large B-cell lymphoma","volume":"29","author":"Sharma","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"24","key":"2026052610380263500_bib16","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell\u2013related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"issue":"4","key":"2026052610380263500_bib17","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"12","key":"2026052610380263500_bib18","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1182\/bloodadvances.2024012637","article-title":"CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity","volume":"8","author":"Hamilton","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"2026052610380263500_bib19","doi-asserted-by":"crossref","first-page":"e57838","DOI":"10.1371\/journal.pone.0057838","article-title":"Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials","volume":"8","author":"Jena","year":"2013","journal-title":"PLOS ONE"},{"issue":"1","key":"2026052610380263500_bib20","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.1991.9.1.191","article-title":"Median follow-up in clinical trials","volume":"9","author":"Shuster","year":"1991","journal-title":"J Clin Oncol"},{"issue":"11","key":"2026052610380263500_bib21","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","article-title":"Long-term systemic corticosteroid exposure: a systematic literature review","volume":"39","author":"Rice","year":"2017","journal-title":"Clin Ther"},{"issue":"suppl 1","key":"2026052610380263500_bib22","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/blood-2023-183002","article-title":"Real world experience with a Zuma-1 cohort 4 adopted approach to CRS and Icans in CAR-T recipients","volume":"142","author":"Sainatham","year":"2023","journal-title":"Blood"},{"issue":"7","key":"2026052610380263500_bib23","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","article-title":"CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results","volume":"29","author":"Park","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"2026052610380263500_bib24","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-024-01048-0","article-title":"Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma","volume":"14","author":"Costa","year":"2024","journal-title":"Blood Cancer J"},{"issue":"2","key":"2026052610380263500_bib25","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3390\/biom13020382","article-title":"Early use of corticosteroids following CAR T-cell therapy correlates with reduced risk of high-grade CRS without negative impact on neurotoxicity or treatment outcome","volume":"13","author":"Lakomy","year":"2023","journal-title":"Biomolecules"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/10\/3313\/2518752\/blooda_adv-2025-019031-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/10\/3313\/2518752\/blooda_adv-2025-019031-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T14:38:13Z","timestamp":1779806293000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/10\/3313\/567292\/Early-steroid-and-anakinra-use-to-manage"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,5,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025019031","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,26]]},"published":{"date-parts":[[2026,5,13]]}}}